| Attribute |
Value |
| 52 Week Change |
-0.608076 |
| Address1 |
9, Rue de Bitbourg |
| All Time High |
18.0 |
| All Time Low |
2.94 |
| Ask |
4.24 |
| Ask Size |
2 |
| Average Analyst Rating |
2.2 - Buy |
| Average Daily Volume10 Day |
632,170 |
| Average Daily Volume3 Month |
713,324 |
| Average Volume |
713,324 |
| Average Volume10Days |
632,170 |
| Beta |
0.192 |
| Bid |
2.36 |
| Bid Size |
2 |
| Book Value |
-0.904 |
| City |
Luxembourg |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
Luxembourg |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
3.335 |
| Current Ratio |
1.755 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,782,777,600 |
| Day High |
3.346 |
| Day Low |
3.28 |
| Earnings Call Timestamp End |
1,778,155,200 |
| Earnings Call Timestamp Start |
1,778,155,200 |
| Earnings Growth |
-0.99 |
| Earnings Quarterly Growth |
-0.991 |
| Earnings Timestamp |
1,778,097,600 |
| Earnings Timestamp End |
1,778,097,600 |
| Earnings Timestamp Start |
1,778,097,600 |
| Ebitda |
104,241,000 |
| Ebitda Margins |
0.18547001 |
| Enterprise To Ebitda |
23.25 |
| Enterprise To Revenue |
4.312 |
| Enterprise Value |
2,423,554,560 |
| Eps Current Year |
0.02682 |
| Eps Forward |
0.23479 |
| Eps Trailing Twelve Months |
-0.28 |
| Esg Populated |
0 |
| Exchange |
NGM |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
3.5643 |
| Fifty Day Average Change |
-0.22930002 |
| Fifty Day Average Change Percent |
-0.06433241 |
| Fifty Two Week Change Percent |
-60.8076 |
| Fifty Two Week High |
9.94 |
| Fifty Two Week High Change |
-6.6049995 |
| Fifty Two Week High Change Percent |
-0.6644869 |
| Fifty Two Week Low |
2.94 |
| Fifty Two Week Low Change |
0.39499998 |
| Fifty Two Week Low Change Percent |
0.13435373 |
| Fifty Two Week Range |
2.94 - 9.94 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,655,386,200,000 |
| Float Shares |
123,166,274 |
| Forward Eps |
0.23479 |
| Forward P E |
14.204183 |
| Free Cashflow |
-92,554,376 |
| Full Exchange Name |
NasdaqGM |
| Full Time Employees |
1,279 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.61534 |
| Gross Profits |
345,844,992 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.5454 |
| Held Percent Institutions |
0.051149998 |
| Implied Shares Outstanding |
338,219,831 |
| Industry |
Drug Manufacturers - Specialty & Generic |
| Industry Disp |
Drug Manufacturers - Specialty & Generic |
| Industry Key |
drug-manufacturers-specialty-generic |
| Ipo Expected Date |
2,022-06-16 |
| Is Earnings Date Estimate |
0 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Long Business Summary |
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg. |
| Long Name |
Alvotech |
| Market |
us_market |
| Market Cap |
1,127,963,136 |
| Market State |
REGULAR |
| Max Age |
86,400 |
| Message Board Id |
finmb_693209405 |
| Most Recent Quarter |
1,774,915,200 |
| Net Income To Common |
-80,731,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
1,116,125,442 |
| Number Of Analyst Opinions |
5 |
| Open |
3.32 |
| Operating Cashflow |
-123,175,000 |
| Operating Margins |
0.091309994 |
| Payout Ratio |
0.0 |
| Previous Close |
3.3 |
| Price Eps Current Year |
124.3475 |
| Price Hint |
4 |
| Price To Book |
-3.6891594 |
| Price To Sales Trailing12 Months |
2.0068982 |
| Profit Margins |
-0.14364 |
| Quick Ratio |
0.67 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
buy |
| Recommendation Mean |
2.2 |
| Region |
US |
| Regular Market Change |
0.035000086 |
| Regular Market Change Percent |
1.0606086 |
| Regular Market Day High |
3.346 |
| Regular Market Day Low |
3.28 |
| Regular Market Day Range |
3.28 - 3.346 |
| Regular Market Open |
3.32 |
| Regular Market Previous Close |
3.3 |
| Regular Market Price |
3.335 |
| Regular Market Time |
1,784,128,620 |
| Regular Market Volume |
66,803 |
| Return On Assets |
0.03839 |
| Revenue Growth |
-0.202 |
| Revenue Per Share |
1.923 |
| Sand P52 Week Change |
0.2043345 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
338,219,831 |
| Shares Percent Shares Out |
0.0086 |
| Shares Short |
2,921,963 |
| Shares Short Previous Month Date |
1,780,012,800 |
| Shares Short Prior Month |
2,933,391 |
| Short Name |
Alvotech |
| Short Percent Of Float |
0.020599999 |
| Short Ratio |
2.46 |
| Source Interval |
15 |
| Symbol |
ALVO |
| Target High Price |
50.0 |
| Target Low Price |
4.0 |
| Target Mean Price |
14.6 |
| Target Median Price |
6.0 |
| Total Cash |
63,832,000 |
| Total Cash Per Share |
0.204 |
| Total Debt |
1,457,281,024 |
| Total Revenue |
562,043,008 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-0.28 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
4.789175 |
| Two Hundred Day Average Change |
-1.454175 |
| Two Hundred Day Average Change Percent |
-0.3036379 |
| Type Disp |
Equity |
| Volume |
66,803 |
| Website |
https://www.alvotech.com |
| Zip |
1,273 |